Abacavir Sulfate 702 762 Mg Eqv Abacavir

證據等級: L5

預測適應症: 0 個

Abacavir Sulfate: Drug Repurposing Evaluation — Insufficient Data for TxGNN Prediction

One-Sentence Summary

Abacavir Sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) widely used in HIV-1 combination antiretroviral therapy worldwide, though it currently has no Singapore HSA registration in this dataset. The TxGNN model was unable to generate any repurposing predictions for this drug in the current pipeline run — most likely due to an unresolved DrugBank ID and a malformed drug name string containing dosage information. This report documents the root causes of pipeline failure and recommends specific remediation steps before re-evaluation.

Quick Overview

Item	Content
Original Indication	Not captured in current dataset
Predicted New Indication	No predictions generated
TxGNN Prediction Score	N/A
Evidence Level	L5 — model prediction stage not reached
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing predictions were generated in this pipeline run, so a mechanism-to-indication rationale cannot be completed at this stage.

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmaceutical knowledge, Abacavir Sulfate is a nucleoside reverse transcriptase inhibitor (NRTI). After intracellular phosphorylation to carbovir triphosphate, it competitively inhibits HIV-1 reverse transcriptase and acts as a chain terminator during viral DNA synthesis. Its efficacy in HIV-1 infection is well-established; its known expected DrugBank entry is DB01048.

The TxGNN pipeline failure most likely has three compounding causes: (1) the inn field contains a full dispensing string — "ABACAVIR SULFATE 702.762 MG EQV. ABACAVIR" — rather than a clean INN, causing the name normalizer to fail to match against the DrugBank vocabulary; (2) the drugbank_id field is null, which prevents the knowledge graph from locating the node for this drug; and (3) the original_indications array is empty, removing a fallback signal for disease context. All three issues must be resolved before the prediction step can proceed.

Clinical Trial Evidence

Currently no related clinical trials registered — no repurposing indication was predicted for this drug in the current pipeline run.

Literature Evidence

Currently no related literature available — no repurposing indication was predicted for this drug in the current pipeline run.

Singapore Market Information

Abacavir Sulfate is currently not registered with Singapore's Health Sciences Authority (HSA) under this drug entry. No active licenses were found in the regulatory dataset.

Note: Abacavir-containing combination products (e.g., Ziagen®, Kivexa®/Epzicom®) may be registered under separate HSA entries. A targeted HSA registry search using the brand name and/or the active ingredient "abacavir" is recommended to confirm actual market presence before concluding the drug is unavailable in Singapore.

Safety Considerations

Please refer to the package insert for safety information.

Known class-level alert (not from Evidence Pack): Abacavir carries a Black Box Warning for hypersensitivity reactions associated with the HLA-B*57:01 allele, and for lactic acidosis/severe hepatomegaly with steatosis. HLA-B*57:01 screening is mandatory before initiation. This information should be formally captured via TFDA/HSA package insert retrieval to close Data Gap DG001.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline did not reach the scoring stage due to a malformed drug name string and a missing DrugBank ID, making it impossible to evaluate any repurposing hypothesis at this time. No safety screening has been completed either, as all warning/contraindication fields remain unresolved.

To proceed, the following is needed:

Fix drug name normalisation — Strip dosage information from the inn field; use clean INN "abacavir" as the query string
Resolve DrugBank ID — Query DrugBank API for "abacavir"; expected result: DB01048
Populate original_indications — After DrugBank resolution, extract approved indications (HIV-1 infection) to provide disease context for the pipeline
Obtain MOA data — Retrieve mechanism of action from DrugBank after ID resolution (closes DG002)
Retrieve Singapore/HSA package insert — Search HSA registry for Ziagen® or Kivexa® to obtain warnings and contraindications (closes DG001)
Re-run TxGNN prediction pipeline — After all above remediation steps, re-run to generate ranked repurposing candidates
Confirm Singapore market presence — Perform a targeted HSA registry search by ingredient name before concluding "Not marketed"
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.